(R)-ACX is a novel sufonylurea compound with potent, quick and short- lasting hypoglycemic activity

European Journal of Pharmacology

Volumn 389, Issue 2-3, 2000, Pages 253-256

  Seri, Kenji ^a   Sanai, Kazuko ^a   Kurashima, Katsumi ^a   Imamura, Yorishige ^b   Akita, Hiroyuki ^c  

^a Central Research Laboratory   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c TOHO UNIVERSITY   (Japan)

Author keywords

(R) ACX; Hypoglycemic effect; Insulin releasing effect; Sulfonylurea compound

Indexed keywords

4 (1 ACETOXYETHYL) N (CYCLOHEXYLCARBAMOYL)BENZENESULFONAMIDE ACETOXYHEXAMIDE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG ABSORPTION; DRUG EFFECT; DRUG ELIMINATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME SYNTHESIS; HAMSTER; HYPOGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL;

ACETOHEXAMIDE; ANIMALS; BLOOD GLUCOSE; CELL LINE; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYBURIDE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED ICR; RATS; RATS, WISTAR; SULFONYLUREA COMPOUNDS;

EID: 0034681362     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00922-X     Document Type: Article

References (10)

1. Akita H., Kurashima K., Nozawa M., Yamamura S., Seri K., Imamura Y. Determination of absolute configuration of a metabolite (-)-hydroxyhexamide from acetohexamide, syntheses of (-)- and (+)-hydroxyhexamides and (-)- and (+)-acetoxyhexamides. Tetrahedron: Asymmetry. 9:1998;4331-4340.
2. Ikenoue T., Akiyoshi M., Fujitani S., Okazaki K., Kondo N., Miki T. Hypoglycemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexane-carbonyl)-D-phenylalanine (A-4166). Br. J. Pharmacol. 120:1997;137-145.
3. Jackson J., Bessler R. Clinical pharmacology of sulfonylurea hypoglycemic agents. Drugs. 22:1981;211-245.
4. Jennings A., Wilson R., Ward J. Symptomatic hypoglycemia NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 12:1989;203-208.
5. Lebovitz H.E. Oral antidiabetic agents: the emergence of α-glucosidase inhibitors. Drugs. 44(Suppl. 3):1992;21-28.
6. McMahon R.E., Marshall F.J., Culp H.W. The nature of the metabolites of acetohexamide in the rat and in the human. J. Pharmacol. Exp. Ther. 149:1965;272-279.
7. Ohnota H., Koizumi T., Tsutsumi N., Kobayashi M., Inoue S., Sato F. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinycarbonyl)propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J. Pharmacol. Exp. Ther. 269:1994;489-495.
8. Ohta T., Furukawa N., Yonemori F., Wakitani K. JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetic mellitus rats. Eur. J. Pharmacol. 367:1999;91-99.
9. Takagishi Y., Sato K., Tomita K., Sakamoto T. High-performance liquid chromatographic determination of acetohexamide and its metabolite, hydroxyhexamide. Yakugaku Zasshi. 99:1979;961-963.
10. Toeller M. Nutritional recommendations for diabetic patients and treatment with α-glucosidase inhibitors. Drugs. 44(Suppl. 3):1992;13-20.